The Association Between Molecular Typing of Treponema Pallidum and Treatment Efficacy and Clinical Findings

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02871505

Enrollment

150

Registered

2016-08-18

Start date

2016-08-31

Completion date

2020-08-31

Last updated

2018-11-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Syphilis

Brief summary

The investigators compare the treatment results and clicical presentations of different Molecular subtyping of Treponema pallidum

Interventions

DRUGBenzathine Penicillin G

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

1\. Persons with confirmed early symptomatic syphilis (primary or secondary) or high-titer latent syphilis

Exclusion criteria

1. Pregnant woman 2. Known allergy to penicillin 3. RPR titers were found to be 1:8 or less

Design outcomes

Primary

Measure	Time frame
rapid plasma regain titer	6 months after treatment

Countries

China

Contacts

Primary ContactJun Li, M.D.

lijun35@hotmail.com86-010-69151504

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026